For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

A review found that CD4/CD8 ratio could be used as a prognostic marker for mortality in patients with HIV, though future studies need to be done to confirm these findings. Clinical practices can ...

CD4 counts show how strong your immune system is; lower counts mean a weaker immune response. The CD4 percentage shows what part of your white blood cells are CD4 cells and helps check how strong your ...

T lymphocytes play a pivotal role in resolving hepatitis B virus infection. This study aimed to investigate the dynamics of peripheral blood T lymphocyte subsets during peginterferon alpha (peg-IFN-α) ...

Conservation of their respective cytoplasmic tail motifs, CxC/H in the case of CD4 and an ITIM-like motif in the case of LAG-3, supports that competition between CD4 and LAG-3 for binding of kinase ...

In a retrospective study, the non-relapse mortality rate at 1 year was 17% in those with CAR T-cell therapy-associated immune-related adverse events versus 2.7% in those without such events.

Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer The authors report on a prognostic tool (CD3 ...

Abnormal expansion of PD-1+ T lymphocytes may be a sign of lupus nephritis onset in patients with SLE. Elevated PD-1+CD4+ T cells represent an independent risk factor for lupus nephritis (LN) and may ...

Cost analysis of pre-treatment dihydropyrimidine dehydrogenase (DPYD) genotyping to reduce hospitalizations at a cancer center in the United States (U.S.). This is an ASCO Meeting Abstract from the ...